Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Location [1]
Kinase fusions, Receptor tyrosine kinase/growth factor signaling
Protein [2]
High affinity nerve growth factor receptor
Synonyms [1]
TRK, MTC, p140-TrkA, TRK1, TRKA, Trk-A

NTRK1 (neurotrophic tyrosine kinase, receptor, type 1) encodes the high affinity nerve growth factor receptor protein. NTRK1 fusions have been observed in colorectal cancer (PMID: 2869410), papillary thyroid cancer (PMID: 19883730), lung cancer (PMID: 24162815), glioblastoma (PMID: 19883730; PMID: 24647444), and cholangiocarcinoma (PMID: 24563076). NTRK1 fusions trigger constitutive TRKA kinase activity (PMID: 24162815), which activates cell growth and differentiation pathways (PMID: 12652644).

NTRK1 is altered in 2.72% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, cutaneous melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

NTRK1 GENIE Cases - Top Diseases

The most common alterations in NTRK1 are NTRK1 Mutation (1.86%), NTRK1 Amplification (0.48%), NTRK1 Fusion (0.16%), NTRK1 R214W (0.04%), and NTRK1-LMNA Fusion (0.04%) [3].

NTRK1 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of NTRK1 in Diseases

Malignant Solid Tumor +

Non-Small Cell Lung Carcinoma +

Acute Lymphoblastic Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

Melanoma +

Breast Carcinoma +

Acute Myeloid Leukemia +

Head And Neck Squamous Cell Carcinoma +

Colorectal Carcinoma +

Non-Hodgkin Lymphoma +

Lymphoma +

Congenital Mesoblastic Nephroma +

Infantile Fibrosarcoma +

Squamous Cell Lung Carcinoma +

Anaplastic Large Cell Lymphoma +

Lung Carcinoma +

Ovarian Carcinoma +

Cervical Carcinoma +

Pancreatic Carcinoma +

Myelodysplastic Syndromes +

Mixed Phenotype Acute Leukemia +

Gallbladder Carcinoma +

Malignant Uterine Neoplasm +

Lung Adenocarcinoma +

Hepatocellular Carcinoma +

Desmoplastic Small Round Cell Tumor +

Thymoma +

Malignant Colorectal Neoplasm +

Esophageal Squamous Cell Carcinoma +

Head And Neck Carcinoma +

Bladder Carcinoma +

Malignant Ovarian Neoplasm +

Malignant Glioma +

Gastric Adenocarcinoma +

Esophagogastric Carcinoma +

Central Nervous System Neoplasm +

Adenocarcinoma Of The Gastroesophageal Junction +

Chronic Myeloid Leukemia +

Soft Tissue Sarcoma +

Bile Duct Carcinoma +

Kidney Carcinoma +

Prostate Carcinoma +

Multiple Myeloma +

Adenoid Cystic Carcinoma +

Mesothelioma +

Hematopoietic And Lymphoid Malignancy +

Acute Leukemia +

Histiocytic And Dendritic Cell Neoplasm +

B-Cell Lymphoblastic Lymphoma +

Bronchogenic Carcinoma +

Chronic Myelomonocytic Leukemia +

Lymphoblastic Lymphoma +

Mixed Phenotype Acute Leukemia, B/Myeloid, NOS +

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS +

Secondary Acute Myeloid Leukemia +

Secretory Breast Carcinoma +

T-Cell Acute Lymphoblastic Leukemia +

T-Cell Lymphoblastic Lymphoma +

Therapy-Related Acute Myeloid Leukemia +

Thymic Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.